X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3492) 3492
Book Review (1077) 1077
Publication (162) 162
Newsletter (22) 22
Book Chapter (16) 16
Newspaper Article (13) 13
Magazine Article (9) 9
Conference Proceeding (6) 6
Dissertation (2) 2
Book / eBook (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rivaroxaban (2915) 2915
humans (2711) 2711
index medicus (2711) 2711
dabigatran (1574) 1574
anticoagulants - therapeutic use (1516) 1516
anticoagulants (1512) 1512
warfarin (1363) 1363
male (1096) 1096
female (1058) 1058
apixaban (1026) 1026
administration, oral (1008) 1008
atrial fibrillation (935) 935
aged (908) 908
anticoagulants - adverse effects (809) 809
middle aged (737) 737
venous thromboembolism (726) 726
hematology (718) 718
thromboembolism (717) 717
stroke (709) 709
atrial fibrillation - drug therapy (691) 691
anticoagulants - administration & dosage (690) 690
morpholines - therapeutic use (690) 690
prevention (689) 689
thiophenes - therapeutic use (685) 685
rivaroxaban - therapeutic use (664) 664
peripheral vascular disease (613) 613
stroke - prevention & control (597) 597
treatment outcome (575) 575
hemorrhage - chemically induced (569) 569
cardiac & cardiovascular systems (564) 564
pyridones - therapeutic use (534) 534
pyrazoles - therapeutic use (531) 531
pharmacology & pharmacy (521) 521
atrial fibrillation - complications (505) 505
risk factors (501) 501
warfarin - therapeutic use (500) 500
factor xa inhibitors - therapeutic use (467) 467
atrial-fibrillation (454) 454
safety (427) 427
risk (416) 416
thrombosis (412) 412
aged, 80 and over (409) 409
medicine, general & internal (397) 397
dabigatran etexilate (393) 393
factor xa inhibitors (389) 389
adult (375) 375
beta-alanine - analogs & derivatives (372) 372
management (371) 371
benzimidazoles - therapeutic use (368) 368
analysis (367) 367
anticoagulation (366) 366
abridged index medicus (357) 357
drug therapy (357) 357
medicine & public health (345) 345
bleeding (344) 344
venous thromboembolism - prevention & control (343) 343
oral anticoagulants (342) 342
thrombin (339) 339
care and treatment (332) 332
stroke - etiology (323) 323
therapy (320) 320
venous thromboembolism - drug therapy (320) 320
enoxaparin (317) 317
rivaroxaban - adverse effects (314) 314
patients (310) 310
cardiac arrhythmia (306) 306
edoxaban (301) 301
morpholines - adverse effects (300) 300
thiophenes - adverse effects (299) 299
stroke prevention (288) 288
rivaroxaban - administration & dosage (287) 287
dabigatran - therapeutic use (284) 284
deep-vein thrombosis (283) 283
beta-alanine - therapeutic use (278) 278
retrospective studies (275) 275
vitamin k - antagonists & inhibitors (274) 274
cardiology (273) 273
thromboprophylaxis (266) 266
double-blind (255) 255
clinical trials (254) 254
factor xa inhibitor (254) 254
pharmacokinetics (254) 254
morpholines - administration & dosage (252) 252
thiophenes - administration & dosage (252) 252
factor-xa inhibitor (251) 251
anticoagulants - pharmacology (248) 248
blood coagulation - drug effects (247) 247
warfarin - adverse effects (242) 242
dosage and administration (241) 241
pyridines - therapeutic use (238) 238
hemorrhage (237) 237
direct oral anticoagulants (234) 234
factor xa inhibitors - adverse effects (232) 232
pyridones - administration & dosage (232) 232
pyrazoles - administration & dosage (231) 231
surgery (230) 230
pyrazoles - adverse effects (228) 228
pyridones - adverse effects (228) 228
efficacy (227) 227
randomized controlled trials as topic (226) 226
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3273) 3273
German (75) 75
French (58) 58
Spanish (38) 38
Russian (23) 23
Italian (11) 11
Chinese (10) 10
Japanese (7) 7
Czech (6) 6
Hungarian (6) 6
Polish (6) 6
Swedish (6) 6
Turkish (6) 6
Portuguese (5) 5
Dutch (3) 3
Finnish (3) 3
Danish (2) 2
Ukrainian (2) 2
Korean (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Index Medicus | Abridged Index Medicus | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article